https://zentalis.com/publications/a-phase-1b-dose-escalation-study-of-zn-c3-a-wee1-inhibitor-in-combination-with-chemotherapy-in-patients-with-platinum-resistant-or-refractory-ovarian-peritoneal-or-fallopian-tube-cancer/ 2026-03-01T22:24:02+00:00 https://zentalis.com/publications/trial-in-progress-cyclin-e1-positive-protein-status-is-a-predictive-biomarker-of-azenosertib-benefit-in-platinum-resistant-ovarian-cancer-part-2-of-the-denali-study-gog-3066/ 2026-04-03T18:52:50+00:00 https://zentalis.com/publications/results-from-the-phase-1-dose-escalation-and-dose-expansion-study-of-azenosertib-a-wee1-inhibitor-in-patients-with-advanced-solid-tumors/ 2026-04-03T18:54:08+00:00 https://zentalis.com/publications/rationale-for-the-use-of-azenosertib-in-early-line-treatment-of-cyclin-e1-positive-high-grade-serous-ovarian-cancer/ 2026-04-03T18:54:28+00:00 https://zentalis.com/publications/trial-in-progress-phase-1-study-of-trastuzumab-deruxtecan-ds-8201a-in-combination-with-azenosertib-zn-c3-in-her2-expressing-amplified-gastric-gastroesophageal-junction-cancer-and-other-solid-tu/ 2026-04-03T18:56:02+00:00 https://zentalis.com/publications/phase-1-dose-escalation-results-of-the-wee-inhibitor-azenosertib-in-combination-with-encorafenib-and-cetuximab-in-patients-with-previously-treated-brafv600e-mutant-metastatic-colorectal-cancer/ 2026-04-03T18:57:55+00:00 https://zentalis.com/publications/azenosertib-is-a-potent-and-selective-wee1-kinase-inhibitor-with-broad-antitumor-activity-across-a-range-of-solid-tumors-2/ 2026-04-03T19:01:26+00:00 https://zentalis.com/publications/azenosertib-is-a-potent-and-selective-wee1-kinase-inhibitor-with-broad-antitumor-activity-across-a-range-of-solid-tumors/ 2026-04-03T19:03:45+00:00 https://zentalis.com/publications/cell-free-dna-molecular-response-predicts-clinical-efficacy-in-hgsoc-patients-treated-with-azenosertib/ 2026-04-03T19:05:31+00:00 https://zentalis.com/publications/loss-of-rb1-sensitizes-tp53-mutated-cancer-cells-to-wee1-inhibition-by-azenosertib/ 2026-04-03T19:07:46+00:00 https://zentalis.com/publications/cyclin-e1-is-a-predictive-biomarker-of-azenosertib-benefit-in-platinum-resistant-ovarian-cancer-proc-outcomes-from-part-1b-of-the-denali-study-gog-3066/ 2026-04-03T19:11:02+00:00 https://zentalis.com/publications/cyclin-e1-cdk2-activation-defines-a-key-vulnerability-to-wee1-kinase-inhibition-in-gynecologic-cancers/ 2026-04-03T19:12:10+00:00 https://zentalis.com/publications/the-selective-wee1-inhibitor-azenosertib-shows-synergistic-antitumor-activity-with-krasg12c-inhibitors-in-multiple-krasg12c-models/ 2026-04-03T19:24:09+00:00 https://zentalis.com/publications/the-wee1-inhibitor-azenosertib-shows-synergistic-antitumor-effects-with-microtubule-inhibitor-based-antibody-drug-conjugates-adcs-in-preclinical-models/ 2026-04-03T19:26:23+00:00 https://zentalis.com/publications/the-selective-wee1-inhibitor-azenosertib-shows-synergistic-antitumor-effects-in-combination-with-topoisomerase-1-inhibitor-based-antibody-drug-conjugates/ 2026-04-03T19:29:01+00:00 https://zentalis.com/publications/the-selective-wee1-inhibitor-azenosertib-shows-synergistic-antitumor-activity-with-krasg12c-inhibitors-in-preclinical-models/ 2026-04-03T19:29:58+00:00 https://zentalis.com/publications/phase-1-results-of-the-wee1-inhibitor-azenosertib-in-combination-with-gemcitabine-in-adult-and-pediatric-patients-with-relapsed-or-refractory-osteosarcoma/ 2026-04-03T19:31:47+00:00 https://zentalis.com/publications/correlation-of-cyclin-e1-expression-and-clinical-outcomes-in-a-phase-1b-dose-escalation-study-of-azenosertib-zn-c3-a-wee1-inhibitor-in-combination-with-chemotherapy-ct-in-patients-pts-with-pla/ 2026-04-03T19:33:25+00:00 https://zentalis.com/publications/cyclin-e1-positive-staining-is-frequent-and-independent-of-prior-platinum-treatment-in-high-grade-serous-ovarian-cancer/ 2026-04-03T19:35:04+00:00 https://zentalis.com/publications/cyclin-e1-protein-overexpression-sensitizes-ovarian-cancer-cells-to-azenosertib-zn-c3-a-novel-selective-and-orally-bioavailable-inhibitor-of-wee1/ 2026-04-03T19:36:07+00:00 https://zentalis.com/publications/tumor-pharmacokinetics-pharmacodynamics-and-efficacy-analysis-of-wee1-inhibitor-azenosertib-in-patientderived-xenograft-models-of-glioblastoma/ 2026-04-03T19:38:59+00:00 https://zentalis.com/publications/a-phase-1-2-dose-escalation-and-dose-expansion-study-of-zn-c3-in-combination-with-gemcitabine-in-adult-and-pediatric-subjects-with-relapsed-or-refractory-osteosarcoma/ 2026-04-03T19:40:36+00:00 https://zentalis.com/publications/a-phase-1b-dose-escalation-study-of-zn-c3-a-wee1-inhibitor-in-combination-with-chemotherapy-ct-in-subjects-with-platinum-resistant-or-refractory-ovarian-peritoneal-or-fallopian-tube-cancer/ 2026-04-03T19:41:43+00:00 https://zentalis.com/publications/bh3-mimetics-synergize-with-the-wee1-inhibitor-zn-c3-by-activating-caspases-which-induce-dna-damage-and-degrade-key-proteins/ 2026-04-03T19:42:58+00:00 https://zentalis.com/publications/preliminary-data-from-a-phase-1-dose-escalation-study-of-zn-c3-plus-gemcitabine-in-relapsed-refractory-osteosarcoma/ 2026-04-03T19:44:51+00:00 https://zentalis.com/publications/safety-and-clinical-activity-of-single-agent-zn-c3-an-oral-wee1-inhibitor-in-a-phase-1-trial-in-subjects-with-recurrent-or-advanced-uterine-serous-carcinoma-usc/ 2026-04-03T19:45:59+00:00 https://zentalis.com/publications/zn-c3-a-potent-and-selective-wee1-inhibitor-demonstrates-anti-tumor-activities-in-combination-with-other-targeted-therapies-and-overcomes-parp-inhibitor/ 2026-04-03T19:49:05+00:00 https://zentalis.com/publications/discovery-of-zn-c3-a-highly-potent-and-selective-wee1-inhibitor-undergoing-evaluation-in-clinical-trials-for-the-treatment-of-cancer/ 2026-04-03T19:51:48+00:00 https://zentalis.com/publications/discovery-of-zn-c3-a-potent-wee1-inhibitor-with-a-differentiated-pharmacologic-and-kinase-selectivity-profile/ 2026-04-03T19:53:08+00:00 https://zentalis.com/publications/pharmacodynamic-evidence-for-wee1-target-engagement-in-surrogate-and-tumor-tissues-from-a-phase-1-study-of-the-wee1-inhibitor-zn-c3/ 2026-04-03T19:54:25+00:00 https://zentalis.com/publications/the-selective-wee1-inhibitor-azenosertib-shows-synergistic-anti-tumor-activity-with-encorafenib-cetuximab-in-multiple-brafv600e-models/ 2026-04-22T19:06:57+00:00